Context Therapeutics financials
$0.3190−2.24%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$15.0M | -$9.3M | -$13.8M | -$10.6M | -$9.8M | -$5.5M | -$4.3M | -$18.7M | -$3.1M | -$3.8M | -$6.9M | -$6.2M |
| Net income | -$14.6M | -$8.7M | -$13.0M | -$9.7M | -$8.8M | -$4.6M | -$3.3M | -$17.5M | -$2.3M | -$3.7M | -$6.8M | -$5.9M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.15 | $-0.09 | $-0.14 | $-0.10 | $-0.09 | $-0.05 | $-0.04 | $-0.22 | $-0.04 | $-0.23 | $-0.42 | $-0.37 |
| EBITDA | -$15.0M | -$9.3M | -$13.8M | -$10.6M | -$9.8M | -$5.5M | -$4.3M | -$18.7M | -$3.1M | -$3.8M | -$6.9M | -$6.2M |
| Operating cash flow | -$7.0M | -$11.4M | -$8.9M | -$6.6M | -$5.8M | -$5.0M | -$4.9M | -$1.9M | -$3.4M | -$4.4M | -$7.2M | -$3.5M |
| Free cash flow | -$7.0M | -$11.5M | -$8.9M | -$6.6M | -$5.8M | -$5.1M | -$4.9M | -$1.9M | -$3.4M | -$4.4M | -$7.2M | -$3.5M |
| Diluted shares | 95.2M | 95.2M | 95.2M | 95.2M | 95.2M | 95.2M | 82.3M | 80.5M | 55.0M | 16.0M | 16.0M | 16.0M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $43.0M | $54.5M | $66.0M | $76.9M | $83.5M | $89.4M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $46.1M | $58.9M | $68.5M | $79.2M | $87.2M | $93.0M |
| Total liabilities | $8.0M | $6.7M | $8.0M | $6.1M | $4.6M | $2.0M |
| Shareholders' equity | $38.2M | $52.2M | $60.5M | $73.2M | $82.5M | $91.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology